SIRT1 and familial pancreatic carcinoma: The downregulation of β-catenin via SIRT1 activation effectively inhibits pancreatic cancer cell proliferation, highlighting the therapeutic potential of SIRT1 in targeting β-catenin-driven oncogenic pathways in pancreatic cancer.